Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain
Park JH, Liu Y, Lemmon MA, Radhakrishnan R. Erlotinib binds both inactive and active conformations of the EGFR tyrosine kinase domain. Biochemical Journal 2012, 448: 417-423. PMID: 23101586, PMCID: PMC3507260, DOI: 10.1042/bj20121513.Peer-Reviewed Original ResearchOccupy EGFR
Park JH, Lemmon MA. Occupy EGFR. Cancer Discovery 2012, 2: 398-400. PMID: 22588876, PMCID: PMC3354646, DOI: 10.1158/2159-8290.cd-12-0144.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsBrain NeoplasmsErbB ReceptorsErlotinib HydrochlorideGliomaHumansLung NeoplasmsProtein Kinase InhibitorsQuinazolinesConceptsEpidermal growth factor receptor (EGFR) mutationsNon-small cell lung cancer (NSCLC) tumorsCell lung cancer tumorsDifferent EGFR mutationsTreatment of glioblastomaLung cancer tumorsDistinct receptor conformationsEGFR mutationsReceptor mutationsEGFR inhibitorsCancer tumorsInhibitor efficacyEGFR mutantsEGFR variantsEGFRGlioblastomaDrug selectivityReceptor conformationNew studiesBarkovichErlotinibGefitinibTumors